SCHEMBL9968909

SCHEMBL9968909

COC(=O)c1cc(/C(N)=N/O)ccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.47
LMNA P02545 5/20 0.47
MAPT P10636 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 4/20 0.47
RECQL P46063 1/20 0.45
HPGD P15428 5/20 0.44
GAA P10253 3/20 0.44
GLA P06280 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
ATM Q13315 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TSHR P16473 1/20 0.44
RAB9A P51151 6/20 0.43
ABL1 P00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2772950 1.00 SMN1; SMN2 (0.47) SMN1; SMN2LMNAMAPTMEN1KMT2A
SCHEMBL2772953 1.00 SMN1; SMN2 (0.47) SMN1; SMN2LMNAMAPTMEN1KMT2A
SCHEMBL406844 0.88 RAB9A (0.51) SMN1; SMN2LMNAMAPTKDM4EALDH1A1
SCHEMBL9968899 0.88 RAB9A (0.51) SMN1; SMN2LMNAMAPTKDM4EALDH1A1
SCHEMBL406845 0.88 RAB9A (0.51) SMN1; SMN2LMNAMAPTKDM4EALDH1A1
SCHEMBL2803617 0.83 CA12 (0.56) SMN1; SMN2LMNAMAPTMEN1KMT2A
SCHEMBL20184057 0.83 KMT2A (0.48) SMN1; SMN2LMNAMAPTKMT2AKDM4E
SCHEMBL20184054 0.83 KMT2A (0.48) SMN1; SMN2LMNAMAPTKMT2AKDM4E
SCHEMBL16709906 0.83 MEN1 (0.48) SMN1; SMN2LMNAMAPTMEN1KMT2A
SCHEMBL9968901 0.83 CA12 (0.56) SMN1; SMN2LMNAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2193125-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-01-11 EP disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
WO-2009043889-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240658-A1 Oxadiazole Derivatives OXA1L, RO60, NQO2 SMN1; SMN2 1346/4885LMNA 4578/4885MAPT 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.